Biocon, India’s largest biopharmaceutical company, said its total revenue for the fourth quarter of the 2022 fiscal year was up 21% largely due to significant growth in the sales of the company’s biosimilars and generic drugs.
Biocon, India’s largest biopharmaceutical company, said its total revenue for the fourth quarter of the 2022 fiscal year was up 21% largely due to significant growth in the sales of the company’s biosimilars and generic drugs.
Get updates delivered right to your inbox!
